IM011021: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Subjects with Systemic Lupus Erythematosus
|Effective start/end date
|2/1/18 → 12/31/21
- BRISTOL-MYERS SQUIBB COMPANY
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.